MARKET

LYEL

LYEL

Lyell Immunopharma, Inc.
NASDAQ
11.61
-0.88
-7.05%
After Hours: 11.85 +0.24 +2.07% 17:31 06/26 EDT
OPEN
12.38
PREV CLOSE
12.49
HIGH
12.68
LOW
11.47
VOLUME
1.70M
TURNOVER
--
52 WEEK HIGH
45.00
52 WEEK LOW
8.46
MARKET CAP
270.91M
P/E (TTM)
-0.8948
1D
5D
1M
3M
1Y
5Y
1D
Lyell Immunopharma to join H.C. Wainwright Cell Therapy Virtual Conference fireside chat
PUBT · 3d ago
Weekly Report: what happened at LYEL last week (0615-0619)?
Weekly Report · 6d ago
Lyell Immunopharma initial beneficial ownership filing names Innovative Cellular Therapeutics Holdings as 10% owner
PUBT · 06/18 20:07
Lyell Immunopharma Shareholders Back Governance at 2026 Meeting
TipRanks · 06/15 20:59
Lyell Immunopharma shareholders approved auditor Ernst & Young for 2026 fiscal year
PUBT · 06/15 20:06
Lyell Immunopharma Price Target Maintained With a $34.00/Share by Citizens
Dow Jones · 06/15 14:12
Citizens Reiterates Market Outperform on Lyell Immunopharma, Maintains $34 Price Target
Benzinga · 06/15 14:03
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Ascendis Pharma (ASND) and Lyell Immunopharma (LYEL)
TipRanks · 06/15 11:20
More
About LYEL
Lyell Immunopharma, Inc. is a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with hematologic malignancies and solid tumors. The Company’s product candidates include LYL314 and LYL273. Its LYL314, which is in Phase I/II clinical development, is a dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19-targeted CAR T-cell therapies and is under evaluation trial for the treatment of patients with relapsed and/or refractory large B-cell lymphoma. The Company has acquired the global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Webull offers Lyell Immunopharma Inc stock information, including NASDAQ: LYEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LYEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LYEL stock methods without spending real money on the virtual paper trading platform.